Heritage Cannabis Announces Affiliate Endocanna Enters Strategic Partnership With OMNI Medical Services

Rhea-AI Summary

Heritage Cannabis Holdings Corp. (CSE: CANN, OTCQX: HERTF) announced a strategic partnership with OMNI Medical Services. This collaboration will facilitate a significant study to determine optimal cannabis strains for patients by analyzing their endocannabinoid systems. Endocanna Health, in which Heritage holds a 30% interest, will provide EndoDNA test kits for this research. CEO David Schwede emphasized the potential of this partnership to enhance understanding of medical cannabis benefits, particularly in treating COVID-19 patients.

Positive

• Strategic partnership with OMNI Medical Services may enhance research capabilities.
• Endocanna's EndoDNA kits could lead to improved patient outcomes in cannabis treatment.

Negative

• None.

TORONTO--(BUSINESS WIRE)-- Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that Endocanna Health (“Endocanna”), a company in which Heritage holds a 30% non-controlling interest, has entered into a strategic partnership with OMNI Medical Services (“OMNI”). OMNI is a multi-state operator of medical cannabis clinics, evaluations, research, pain management, and online pharmacy services.

Under the partnership, OMNI is preparing a major study in collaboration with Endocanna to determine the best strain of plant-based medicines for patients by analyzing their endocannabinoid system. Endocanna’s EndoDNA test kits analyze essential biomolecules in the human endocannabinoid system to formulate and identify the ratios of CBD and cannabis the body metabolizes most effectively, and explores optimal methods of consumption and dosing based on metabolic function and drug to drug interactions.

“We are impressed with the advancements being made by Endocanna in helping medical cannabis patients discover their own unique responses to cannabinoids and terpenes,” stated David Schwede, CEO of Heritage. “The partnership between OMNI and Endocanna will help accelerate the understanding of the medical benefits of cannabis, including the exciting potential for the use of cannabis products in the treatment of and recovery for those experiencing COVID-19.”

About Heritage Cannabis Holdings Corp.
Heritage Cannabis is a leading cannabis company offering innovative products to both the medical and recreational legal cannabis markets in Canada and the U.S., operating under two licensed manufacturing facilities in Canada. The company has an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, feelgood., the CB4 suite of medical products in Canada and ArthroCBD in the U.S.

ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.

“David Schwede”
David Schwede
CEO

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220118006265/en/

Kelly Castledine

647-660-2560

Source: Heritage Cannabis Holdings Corp.

FAQ

What is Heritage Cannabis Holdings Corp's recent announcement regarding HERTF?

Heritage Cannabis Holdings Corp. announced a strategic partnership with OMNI Medical Services to conduct a major study on medical cannabis.

How does the partnership with OMNI Medical Services benefit Heritage Cannabis?

The partnership may enhance research capabilities and improve patient outcomes by analyzing the endocannabinoid system.

What is the role of Endocanna Health in the partnership announced by Heritage?

Endocanna Health, in which Heritage holds a 30% stake, will provide EndoDNA test kits for the collaborative research.

What potential benefits of cannabis are highlighted in Heritage's press release?

The press release emphasizes the potential medical benefits of cannabis, particularly for patients recovering from COVID-19.